Aim To determine the prevalence and causes of blindness and visual impairment among aged 50 years and older population in Sudurpaschim Province of Nepal. Methods A cross sectional study, among population aged 50 years and older using a random multistage cluster sampling procedure. Eligible study participants were enrolled by door-to-door enumeration. Survey team lead by an Ophthalmologist assessed visual acuity, examination of eye and data collection was carried out on tablets installed with mRAAB 7 software. Results The survey examined 4573 out of 4615 subjects enumerated, with a response rate 99.1%. Out of 4573 subjects, 1995 (43.63%) were male and 2578 (56.37%) were female. Among the examined, 2214 (48.4%) were between 50-59 years. The age- and sex-adjusted prevalence of blindness was 0.6% (95% CI 0.3 – 0.87).The age- and sex-adjusted prevalence of severe visual impairment, moderate visual impairment, and early visual impairment were 1.0% (95% CI 0.6 – 1.3), 5.3% (95% CI 4.5 – 6.2) and 7.0% (95% CI 6.0 – 8.0) respectively. The main causes of bilateral blindness were untreated cataract (36.4%), non-trachomatous corneal opacity (24.2%), glaucoma (21.2%), globe or central nervous system abnormalities (9.1%), age related macular degeneration (6.1%) and other posterior segment diseases (3.0%). Conclusion Prevalence of blindness was reduced in the province in comparison to the previous survey. Cataract remains the major cause of blindness, severe visual impairment, and moderate visual impairment followed by corneal opacities and glaucoma. The study suggests more attention to be given for cataract, corneal blindness and glaucoma in future interventions to eliminate blindness.

The authors have declared no competing interest.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Not Applicable

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Nepal Health Research Council Approval Number - 22

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Not Applicable

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Not Applicable

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Not Applicable

All relevant data are within the manuscript and its Supporting Information files.